Does your competent? doctor have enough functioning brain cells to add this therapy to all these previous ones? NO? You DON'T have any light therapy? RUN AWAY! and your doctor needs to be fired for incompetence! I take no prisoners in trying to get stroke solved, and that means firing a lot of Ph.Ds. and MDs.
near infrared light (5 posts to August 2015)
blue light (9 posts to February 2017)
light therapy (13 posts to December 2011)
light-activated therapy (1 post to October 2013)
- flickering light
(3 posts to February 2020)
Oh, you have nothing from this earlier research! So, you don't have a functioning stroke doctor, do you?
Different light color temperatures in the morning on the effectiveness of rehabilitation training in patients with ischemic stroke: a prospective, single-center, randomized controlled clinical trial
Abstract
Background
Stroke is a leading cause of death and disability worldwide, especially in China, where its incidence is rising. Post-stroke rehabilitation is crucial for restoring neurological function and improving quality of life. Light therapy, a non-pharmacological intervention, is gaining attention for its potential to promote neuroplasticity and enhance brain circulation. Warm and cold light, characterized by different color temperatures, have demonstrated beneficial effects on sleep quality, neurological recovery, and emotional well-being in stroke patients. However, the underlying mechanisms remain incompletely understood. This study explores the effects of different light color temperatures on stroke recovery to optimize rehabilitation approaches.
Methods
The study was designed as a prospective, single-center, randomized controlled trial. 48 patients with ischemic stroke were randomly divided into three groups (1:1:1): warm light group (WLG, 500 lx, 3000 K, n = 16), cold light group (CLG, 500 lx, 6500 K, n = 16), and control group (CG, 500 lx, 5000 K, n = 16). Patients in all three groups received 60 min of rehabilitation therapy daily, from Monday to Friday between 8:30 and 9:30 AM, under light environments with different color temperatures. National Institutes of Health Stroke Scale (NIHSS), Short Form-36 (SF-36), Self-Rating Sleep Scale (SRSS), and levels of interleukin 6 (IL-6), norepinephrine (NE) and melatonin (MT) were measured before and after 4 weeks of intervention.
Results
After 4 weeks intervention, CLG showed a significant reduction of NIHSS when compared to CG(p < 0.001, partial η2 = 0.316) and WLG(p = 0.003, partial η2 = 0.237). Although all three groups showed significant reductions in SRSS scores in the within-group comparisons, between-group comparisons revealed that CLG demonstrated a significantly greater reduction in SRSS compared to CG (p = 0.004, partial η2 = 0.253) and WLG (p = 0.007, partial η2 = 0.241). Regarding the SF-36, the physical component summary (PCS) score significantly decreased in both CG (Δ = –5.34 ± 7.35, p = 0.011) and WLG (Δ = –3.63 ± 4.68, p = 0.015), while CLG showed a significant improvement (Δ = 4.28 (8.78), p = 0.024). Between-group analysis demonstrated that post-intervention PCS scores were significantly higher in CLG compared to CG (p = 0.001, partial η2 = 0.323) and WLG (p = 0.002, partial η2 = 0.326), with no significant difference between CG and WLG (p = 0.104). Mental component summary (MCS) scores showed no statistically significant differences either within or between groups. No significant changes in NE and IL-6 levels were observed across all groups. CLG showed a significant reduction of MT when compared to WLG(p = 0.018, partial η2 = 0.174). No apparent adverse events were reported.
Conclusions
This study demonstrated that cold light therapy significantly improves neurological function, sleep quality, physical health status, including better performance on the physical component of quality of life in post-stroke patients, while warm light shows moderate benefits in sleep. These results support the integration of light-based interventions as adjunctive strategies in post-stroke care.
Trial registration The study was registered in Chinese Clinical Trial Registry as a clinical trial ID (ChiCTR2200057541), March 14, 2022.
No comments:
Post a Comment